- Home
- MAZE
as 05-13-2025 4:00pm EST
Stocks
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 367.0M | IPO Year: | 2025 |
| Target Price: | $25.67 | AVG Volume (30 days): | 199.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.25 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.71 - $17.00 | Next Earning Date: | 01-01-0001 |
| Revenue: | $167,500,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | -98.1% | Revenue Growth (next year): | N/A |
Latest MAZE THERAPEUTICS INC News
MAZE Breaking Stock News: Dive into MAZE Ticker-Specific Updates for Smart Investing
GlobeNewswire
21 hours ago
Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference
Simply Wall St.
a month ago
US Market's Undiscovered Gems Featuring ZJK Industrial And 2 More Small Caps
GlobeNewswire
a month ago
Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights
Investing.com
3 months ago
Maze Therapeutics receives positive ratings following recent IPO
Clinical Trials Arena
3 months ago
Maze Therapeutics doses first subject in Phase II AKD treatment trial
GlobeNewswire
3 months ago
Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease
MT Newswires
3 months ago
Maze Therapeutics Prices Upsized IPO at $16 Per Share
Bloomberg
3 months ago
Drugmakers Metsera and Maze Raise Combined $415 Million in IPOs
Compare MAZE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MAZE MAZE THERAPEUTICS INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.